India Globalization Capital, Inc. (NYSE MKT: IGC) is a company in transition, now targeting pharmaceutical development in the U.S., while curtailing other businesses such as electronics trading in Hong Kong. IGC long-term plans are to establish and extend its development of phytocannabinoid-based pharmaceutical products to treat diseases such as epilepsy and cachexia.
ABcann is new to the public market, having launched its initial public offering on May 4. However, the company is one of the most experienced Canadian growers.
Now, India Globalization Capital, Inc. (NYSE MKT: IGC) is taking a leaf from the Sony playbook. This pioneering company is a ‘first mover’ in the cannabinoid combination therapy space.
Growing marijuana in North America, for obvious reasons, has historically been an underground affair. Amid growing legalization in favor of recreational and medicinal use, growing cannabis on mass scale is rapidly becoming a necessity for companies in a burgeoning industry driven by incredible consumer demand.
ChineseInvestors.com, Inc. (OTCQB: CIIX) is offering a unique opportunity for investors as the company pursues a multi-pronged approach to conquering the rapidly expanding global markets in cannabidiol products and the medical marijuana space in Canada. The company aims to be the world’s leading publicly traded Chinese nutritional company.
One of the very first licensed producers and a pioneer in Canadian medical cannabis, ABcann Global Corporation (TSX.V: ABCN) (OTCQB: ABCCF) has always held to meticulous specifications in the production of its pharmaceutical grade, plant-based medicines.
Algae Dynamics Corp (OTCQB: ADYNF) is focused on developing proprietary research and products involving botanical oils derived from cannabis and algae.
Cannabidiol (CBD) has been scientifically shown to be effective in the treatment of certain epilepsies, pain, inflammation and nausea, as well as providing relief from hangover, anxiety and stress.
ChineseInvestors.com, Inc. (OTCQB: CIIX), a company in the business of providing Chinese-speaking investors with real-time market analysis, commentary, and educational services, recently announced its goals for 2017, stating that it plans to develop a CBD oil-based pharmaceutical that could help with the major problem of epilepsy in China.
China represents a past civilization that has sprung many surprises over the centuries, and has given us some of our greatest inventions, including the compass, gunpowder, papermaking, and printing. On par with these innovations has been Traditional Chinese Medicine (TCM), which has relied, in part, on herbal remedies (tui na).
According to the study, patients who received CBD treatment exhibited over 45 percent mean reduction in seizures, and researchers were outspoken in support of further research.
The nutraceutical industry boasts a diversified playing field, and Canada-based Algae Dynamics Corp. (OTCQB: ADYNF) is taking a unique approach to this burgeoning market, focusing on the development of proprietary research and products that combine the health benefits of botanical oils derived from cannabis and algae.
The products under development by Algae Dynamics promise to pack a powerful therapeutic punch, combining the virtues of omega-3s and cannabinoids. Algae Dynamics’ algae oil is high in omega-3s DHA/DPA, which is in demand by the growing multi-billion dollar food and beverage and health care sectors.
ChineseInvestors.com (OTCQB: CIIX) is a leading financial information website for Chinese-speaking investors in the United States and China.
Also known as Lou Gehrig’s disease, ALS is a fatal illness that attacks the nerve cells that control voluntary muscles such as those in the face, arms, legs, and others.
